

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 22, 2020

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 16, 2019 meeting
- IV. Secretary's report
- V. Old Business
 - Update on nicotine replacement therapy utilization
- VI. New Business
 - A. Proposed protocol for Fabry disease products
 - B. Proposed protocol for Lambert-Eaton Myasthenic Syndrome products
 - C. Proposed protocol for Strensiq[®] (asfotase)
- VII. A. Informational Highlights/Reports
 - 1. DXC Technology/NJ HMO 3rd Quarter 2019 Prior Authorization Report
 - 2. Summary of DURB Action Items
 - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
 - (b) Physician-administered/Antiviral drugs by amount paid
 - B. Medication information:
 - (a) HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics
 - (b) FDA Panel Votes 9-7 to Yank Makena Approval
 - (c) Opioid, benzodiazepine coprescription slightly declines after boxed warning
 - (d) FDA too slow in assessing cancer link to blood pressure drugs, watchdog says
- VIII. Referenced Materials
 - A. Approved protocol for Transthyretin-mediated Amyloidosis (ATTR) products
 - B. Approved protocol for Gaucher disease products